Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 56 of 332 for:    DONEPEZIL

Cerebrolysin Compared to Donepezil in Patients With Mild to Moderate Dementia of Alzheimer's Type (DAT) (DAT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01822951
Recruitment Status : Withdrawn
First Posted : April 4, 2013
Last Update Posted : October 26, 2015
Sponsor:
Information provided by (Responsible Party):
Ever Neuro Pharma GmbH

Brief Summary:

The objective of this trial is the global risk-benefit assessment of Cerebrolysin as compared to donepezil in patients with mild to moderate dementia of Alzheimer's Type (DAT). In addition, a traditional approach will be taken based on the evaluation of the separate risk and benefit domains in comparison with donepezil.

Global risk-benefit as compared to donepezil will be analyzed by determining whether the Cerebrolysin group shows a statistically significant non-inferiority with regard to the combined primary safety and efficacy endpoints (weighted multivariate ensemble). The endpoints will be combined by a global multivariate non-parametric procedure, weighting the safety and efficacy part 50:50.


Condition or disease Intervention/treatment Phase
Alzheimer Disease Drug: Cerebrolysin Drug: Donepezil Phase 4

Detailed Description:

This phase IIIb/IV trial involves patients with mild to moderate Alzheimer's Disease in Europe, Canada and Latin America and is designed as a prospective, randomized, double-blind, active-controlled, parallel-group, multicenter, double-dummy trial.

The study endpoint is after 24 weeks. In total, five visits are scheduled in this trial and a follow-up phone call is performed 4 weeks after Visit 5 (Week 24).

The first visit (Screening Visit, Visit 1) identifies participants who are eligible for and interested in this trial.Efficacy and safety parameters are assessed at the Baseline Visit (Visit 2), in Week 6-7 (Visit 3), Week 14-15 (Visit 4) and Week 24 (Visit 5).


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Comparison of Cerebrolysin and Donepezil: A Randomized, Double-blind, Controlled Trial on Efficacy and Safety in Patients With Mild to Moderate Alzheimer's Disease
Estimated Primary Completion Date : September 2016
Estimated Study Completion Date : December 2016


Arm Intervention/treatment
Experimental: Cerebrolysin Verum

Intravenous medication is given in three treatment courses (TC). Each treatment course lasts for two weeks and consists of 10 infusions (5 infusions weekly). For the infusion 2x10 ml Cerebrolysin (215.2 mg/ml) is diluted with 80 ml 0.9% NaCl (saline) to a total volume of 100 ml, i.v.

Placebo for donepezil: 1 tablet per day from TC 1 Day 1 on and 2 tablets per day from Visit 3 - Visit 5, p.o.

Drug: Cerebrolysin

Intravenous medication is given in three treatment courses (TC). Each treatment course lasts for two weeks and consists of 10 infusions (5 infusions weekly). The first treatment course (TC 1) will be in Week 1 and 2, second treatment course (TC 2) will be repeated during Week 9 and 10 and third treatment course (TC 3) during Week 19 and 20.

Placebo for donepezil:1 tablet per day from TC 1 Day 1 on and 2 tablets per day from Visit 3 - Visit 5, p.o.

Other Name: Cognicer, Renacenz

Active Comparator: Donepezil Verum

5-10 mg donepezil: 1x5 mg donepezil as 1 tablet per day from TC 1 Day 1 on and 2x5 mg donepezil as 2 tablets from Visit 3- Visit 5, p.o.

Placebo for Cerebrolysin: 100 ml 0.9% NaCl (saline), i.v. infusion. Intravenous medication is given in three treatment courses (TC). Each treatment course lasts for two weeks and consists of 10 infusions (5 infusions weekly).

Drug: Donepezil

5-10 mg donepezil: 1x5 mg donepezil as 1 tablet per day from TC 1 Day 1 on and 2x5 mg donepezil as 2 tablets from Visit 3- Visit 5, p.o.

Intravenous medication is given in three treatment courses (TC). Each treatment course lasts for two weeks and consists of 10 infusions (5 infusions weekly). The first treatment course (TC 1) will be in Week 1 and 2, second treatment course (TC 2) will be repeated during Week 9 and 10 and third treatment course (TC 3) during Week 19 and 20.

Other Names:
  • Other names:
  • e.g. Aricept, Donesyn




Primary Outcome Measures :
  1. Change from Baseline in ADAS-cog. and CIBIC+ score distribution [ Time Frame: at Week 24 ]

    The ADAS-cog is a psychometric instrument that evaluates cognitive impairment in the assessment of Alzheimer's disease (memory, attention, reasoning, language, orientation and praxis).

    The CIBI+ is a global rating measure which covers the categories general, mental/cognitive state, behavior, and activities of daily living.



Secondary Outcome Measures :
  1. Adverse events [ Time Frame: at Week 24 ]
    descriptive analysis of number, intensity, relation to study medication and action taken

  2. Vital signs [ Time Frame: at Week 24 ]
    descriptive analysis of baseline-changes of blood pressure, heart rate, respiration rate, body temperature and weight

  3. Laboratory tests [ Time Frame: at Week 24 ]
    descriptive analysis of baseline-changes of hematology (e.g. red blood cell count, hematocrit, hemoglobin levels, mean corpuscular volume, mean corpuscular hemoglobin), blood chemistry (e.g. glucose, total cholesterol, high density lipoprotein cholesterol) and urinalysis (glucose, bilirubin, ketones, density, blood, pH, protein, nitrites and leukocytes)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male and female patients ≥50 years of age
  • Diagnosis of probable mild to moderate Alzheimer's disease according to DSM-IV-TR and NINCDS-ADRDA criteria (see section 18.2.1)
  • Screening MMSE score between 15 and 24, both inclusive
  • Modified Hachinski Ischemic score of ≤4
  • Hamilton Depression Scale score ≤10
  • Brain computerized tomography (CT) or brain magnetic resonance imaging (MRI) scans within 12 months prior to screening without evidence of infection, infarction, or other focal lesions and without clinical symptoms suggestive of intervening neurological disease. If no brain CT or brain MRI is available, a brain MRI shall be performed to exclude other causes of dementia-like syndromes.
  • Sufficient language skills to complete all testing without assistance of a language interpreter
  • Ability to perform all sections of the ADAS-cog
  • Good general health without additional diseases expected to interfere with the study
  • Normal B12, folic acid, VDRL, and TSH or without any clinically significant laboratory abnormalities that would be expected to interfere with the study.
  • ECG and chest x-ray (if available) without clinically significant laboratory abnormalities that would be expected to interfere with the study.
  • Patient is not of childbearing potential (i.e., women must be two years post-menopausal or surgically sterile)
  • Responsible caregiver (individual who continuously attends to the needs of the person or dependent adult), who agrees to be present during study conduct.
  • Written informed consent obtained from the patient and caregiver (and legally authorized representative or guardian if different from caregiver) prior to entry into the study (Screening Visit)

Exclusion Criteria:

  • Any abnormalities associated with significant central nervous disease other than Alzheimer's Disease
  • Severe psychotic features, confusion, agitation or behavioral problems within the last three months that could lead to difficulties complying with the protocol
  • Delusional symptoms are often characteristic of Alzheimer's disease, but patients with symptoms so pronounced that they warrant an alternative psychiatric diagnosis are excluded
  • History of alcohol or substance abuse or dependence within the past two years (DSM-IV-TR criteria, see also sections 18.3.1 and 18.3.2)
  • History of schizophrenia, schizoaffective disorder, bipolar affective disorder (DSM-IV-TR criteria)
  • History of newly identified major depressive disorder within eight weeks before Screening Visit (DSM-IV-TR) (see also exclusion criteria 11 and inclusion criteria 5)
  • Any significant systemic illness or unstable medical condition that could lead to difficulties complying with the protocol. Patients with a history of systemic cancer within the past two years are excluded
  • History of myocardial infarction in the past year or unstable or severe cardiovascular disease, including uncontrolled hypertension
  • Any clinically significant laboratory abnormalities on the battery of screening tests (hematology, blood chemistry, urinalysis, ECG, chest x-ray (if available))
  • Uncontrolled insulin-requiring diabetes or non-insulin dependent diabetes mellitus (HbA1c >10.0)
  • Use of any concomitant medication that could affect functioning of the CNS or interfere with efficacy assessment.
  • Patients who in the Investigator's opinion would not comply with study procedures
  • Patients with fragile or thin veins who may not be able to receive many i.v. infusions
  • Patients who in the past have not tolerated treatment with 10 mg donepezil or treatment with a corresponding dose of another cholinesterase inhibitor
  • Patients with history of any epileptic seizure
  • Patients with known or suspected hypersensitivity to Cerebrolysin, donepezil hydrochloride, piperidine derivates or any of the IMPs' excipients

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01822951


Locations
Layout table for location information
Austria
AKh Allgemeines Krankenhaus der Stadt Linz GmbH
Linz, Austria, 4021
Sponsors and Collaborators
Ever Neuro Pharma GmbH
Investigators
Layout table for investigator information
Study Director: Dieter Meier, MD Ever Neuro Pharma GmbH

Publications:
Xiao S, Yan H, Yao P. Efficacy of Cerebrolysin in patients with Alzheimer's disease. Clin. Drug Invest. 2000; 19:43-53.

Layout table for additonal information
Responsible Party: Ever Neuro Pharma GmbH
ClinicalTrials.gov Identifier: NCT01822951     History of Changes
Other Study ID Numbers: EVE-AT-0412
2012-004944-31 ( EudraCT Number )
First Posted: April 4, 2013    Key Record Dates
Last Update Posted: October 26, 2015
Last Verified: October 2015
Keywords provided by Ever Neuro Pharma GmbH:
DAT Study
Additional relevant MeSH terms:
Layout table for MeSH terms
Donepezil
Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Cerebrolysin
Cholinesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Nootropic Agents
Neuroprotective Agents
Protective Agents